A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer
Study of M7824 and cCRT in Patients with Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Sponsor: Merck KGaA
Enrolling: Male and Female Patients
IRB Number: AAAS4684
U.S. Govt. ID: NCT03840902
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess the overall safety and efficacy (how well the drug works) of study drug M7824 in the treatment of unresectable, non-small cell lung cancer. Another purpose is to determine whether use of the study drug in combination with chemoradiation (chemotherapy plus radiation therapy) followed by the study drug will result in greater survival and tumor reduction. The study drug is thought to work by blocking two pathways in tumors that normally allow the tumors to resist attack by the immune system, thus allowing them to grow and spread. By blocking these two pathways, the study drug allows the body's immune system to more effectively attack the tumors and prevent the tumors from spreading. You will randomly be divided into one of two groups for this study. One group will receive either the study drug plus with chemoradiation therapy, followed by more of the study drug, or the FDA approved drug Durvalumab combined with chemoradiation therapy, followed by more Durvalumab.
This study is closed
Brian Henick, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with stage III non-small cell lung cancer? Yes No
Have you had a thoracotamy in the last 3 weeks? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator